Neuroimaging biomarkers in Alzheimer’s disease have already been widely reported; for example, beta amyloid and tau protein burden can be obtained from nuclear imaging such as positron emission tomography (PET) and single-positron-emission computed tomography (SPECT)26. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.